Navigation Links
Cause of effectiveness discovered for a cirrhosis treatment useful in 40 percent of patients
Date:2/27/2008

This release is available in Spanish.

Scientists of the Center for Applied Medical Research (CIMA) of the University of Navarra have discovered the molecular mechanism responsible for the effectiveness of an existing treatment for primary biliary cirrhosis, which combines two substances in order to produce an effect that does not result from either substance separately. The discovery involved the role played by the AE2 protein when the patient is treated with a combination of ursodeoxycholic acid (UDCA) together with glucocorticoids. The research results were recently published in The Journal of Clinical Investigation.

The origin of primary biliary cirrhosis (PBC)-which mostly affects middle-aged women-is still not understood. This pathology is associated with autoimmune phenomena, damage to the biliary vessels of the liver, and a reduction in the production of bile.

In Spain more than 1,000 cases are diagnosed each year, and the total number of patients worldwide is greater than 15,000. Dr. Juan Francisco Medina, Director of the Laboratory of Molecular Genetics of the CIMA, explains that in the present day the diagnosis of this disease, which is generally detected early, permits treatment with UDCA, which is effective in over half of the patients. However, nearly 40% of PBC patients do not respond satisfactorily to monotherapy with UDCA. Therefore, we looked for a combined treatment, and discovered that the combination of UDCA with glucocorticoids was a promising treatment for this group of patients. Those who suffer from this type of cirrhosis have a deficit of AE2, which is the protein for the secretion of bicarbonate in the bile.

The possibility of more cures with fewer transplants

The originality of this recently-published research article consists in relating, for the first time, the combined treatment with UDCA and glucocorticoids with a greater quantity of bicarbonate in the bile, and an improvement of the production of bile by the liver. Specifically, experiments in animal models and cell cultures demonstrate that only the combined treatment with UDCA and glucocorticoids increases the genetic expression of the human protein AE2 in the liver.

Based on available data, Dr. Medina considers that it is advisable to use combined treatment in those cases which present a poor response to monotherapy with UDCA. He proposes the use of a corticoid such as budesonida, which has fewer side effects than cortisone and prednisone. If, for fear of side effects, we allow the disease to progress, it is very probable that the only treatment will be a transplant. On the other hand, if this treatment option is confirmed as successful, it could reduce the number of transplants required in order to save the lives of patients.


'/>"/>

Contact: Oihane Lakar
oihane@elhuyar.com
34-943-363-040
Elhuyar Fundazioa
Source:Eurekalert

Related medicine news :

1. Drug for cluster headaches may cause heart problems
2. Study Points to Cause of Vioxx Heart Risk
3. Damp, Moldy Homes May Cause Depression
4. Constipations Many Causes and Cures
5. High Co-Pays Cause Seniors to Go Without Meds
6. 13 percent of women stop taking breast cancer drug because of side effects, U-M study finds
7. Vocal cord dysfunction may be caused by work
8. Study finds drug spending caps cause some seniors to quit taking key medicines
9. Medicare Spending Caps Cause Seniors to Stop Meds
10. Gene Mutations May Cause Rare Neonatal Diabetes
11. Patent Expiries of Proscar and Flomax/Harnal Will Cause a Significant Decline in Near-Term Sales of Benign Prostatic Hyperplasia Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... ... September 22, 2017 , ... MEDIA OPPORTUNITY: , Save Our Hospital ... citizens on why they are rallying against Mayo Clinic. Specifically, media can talk to ... Dr. Noseworthy’s (CEO) decision to close the Albert Lea hospital. , The rally aims ...
(Date:9/22/2017)... ... , ... After a long health ordeal that involved a ... life with assistance from CreditAssociates. CreditAssociates provides debt relief and debt settlement programs ... senior is one of the satisfied clients who expressed their appreciation for the ...
(Date:9/22/2017)... (PRWEB) , ... September 22, 2017 , ... ... book on the fallacy of an obligatory tithe, and the freedom experienced when ... is the creation of published author, Lysa M. Harrison. , Published by Christian ...
(Date:9/22/2017)... ... ... “Fruit of the Spirit: “Love””: a delightful adventure of two friends who ... the Spirit: “Love”” is the creation of published author, Halimah Jones, who was born ... is an avid writer, her inspiration for “Fruit of the Spirit: “Love”” blossomed from ...
(Date:9/21/2017)... Aliso Viejo, CA (PRWEB) , ... September 21, 2017 , ... ... never been so fun and easy to do. Users can select from up to ... more all with a click of a mouse all within Final Cut Pro ...
Breaking Medicine News(10 mins):
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, ... complete response letter from the U.S. Food and Drug ... approval of sirukumab for the treatment of moderately to ... indicates additional clinical data are needed to further evaluate ... to severely active RA. ...
(Date:9/22/2017)... -- As the latest Obamacare repeal effort moves is debated, ... and Lindsey Graham (R-SC) medical device market ... is in an odd place.  The industry wants repeal ... on medical device sales passed along with the Affordable ... visits and hospital customers with the funding to invest ...
(Date:9/22/2017)... DIEGO , Sept. 22, 2017 AVACEN ... medical device is now successfully helping those with the ... Fibromyalgia diagnosed Amanda in Essex, ... dressed and washing my hair, experiencing no sleep at ... in painful spasm… I cannot recommend [the AVACEN 100] ...
Breaking Medicine Technology: